Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

6533b859fe1ef96bd12b839b

RESEARCH PRODUCT

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

E. Van Cutsem M. Dicato N. Arber J. Berlin A. Cervantes F. Ciardiello A. De Gramont E. Diaz-rubio M. Ducreux R. Geva B. Glimelius R. Glynne-jones Axel Grothey T. Gruenberger D. Haller K. Haustermans R. Labianca H. J. Lenz B. Minsky B. Nordlinger A. Ohtsu Nicholas Pavlidis P. Rougier W. Schmiegel C. Van De Velde H. J. Schmoll A. Sobrero Josep Tabernero E. Van Cutsem M. Dicato N. Arber J. Berlin A. Cervantes F. Ciardiello A. De Gramont E. Diaz-rubio M. Ducreux R. Geva B. Glimelius R. Glynne-jones Axel Grothey T. Gruenberger D. Haller K. Haustermans R. Labianca H. J. Lenz B. Minsky B. Nordlinger A. Ohtsu Nicholas Pavlidis P. Rougier W. Schmiegel C. Van De Velde H. J. Schmoll A. Sobrero Josep Tabernero

subject

Oncology Colorectal cancer medicine.medical_treatment Braf protein Gastroenterology Metastasis Drug antagonism Targeted therapy Metastasis Antineoplastic agents Pathology Conference paper Biological markers Predictive marker Hematology Prognosis Chemotherapy regimen Antineoplastic agent Oncology Proto-oncogene proteins Ras protein Human Receptor medicine.medical_specialty Neoplasm metastasis Ras proteins MEDLINE Oncoprotein Colorectal neoplasms Proto-oncogene proteins b-raf Internal medicine Genetics medicine Humans Gastrointestinal cancer Colorectal tumor B raf kinase Epidermal growth factor receptor Kras protein business.industry Epidermal growth factor Cancer medicine.disease digestive system diseases Biological marker Metabolism Spain Mutation Carcinoembryonic antigen Microsatellite instability business

description

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC. 21 Suppl 6 vi1 10

year	journal	country	edition	language
2010-06-01	Annals of Oncology

https://doi.org/10.1093/annonc/mdq273